首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   176475篇
  免费   17281篇
  国内免费   10905篇
耳鼻咽喉   1712篇
儿科学   2017篇
妇产科学   2461篇
基础医学   20673篇
口腔科学   3223篇
临床医学   21397篇
内科学   24779篇
皮肤病学   2173篇
神经病学   9243篇
特种医学   6480篇
外国民族医学   97篇
外科学   18473篇
综合类   29775篇
一般理论   22篇
预防医学   11790篇
眼科学   4697篇
药学   19606篇
  179篇
中国医学   11196篇
肿瘤学   14668篇
  2024年   153篇
  2023年   2679篇
  2022年   4476篇
  2021年   7734篇
  2020年   7594篇
  2019年   8438篇
  2018年   5441篇
  2017年   5959篇
  2016年   4816篇
  2015年   8179篇
  2014年   10437篇
  2013年   9602篇
  2012年   14053篇
  2011年   15134篇
  2010年   9868篇
  2009年   7621篇
  2008年   10117篇
  2007年   9559篇
  2006年   9211篇
  2005年   8950篇
  2004年   5718篇
  2003年   5199篇
  2002年   4316篇
  2001年   3613篇
  2000年   3846篇
  1999年   3889篇
  1998年   2269篇
  1997年   2334篇
  1996年   1751篇
  1995年   1745篇
  1994年   1536篇
  1993年   919篇
  1992年   1298篇
  1991年   1121篇
  1990年   893篇
  1989年   849篇
  1988年   767篇
  1987年   606篇
  1986年   456篇
  1985年   396篇
  1984年   188篇
  1983年   156篇
  1982年   89篇
  1981年   125篇
  1980年   78篇
  1979年   109篇
  1978年   52篇
  1977年   50篇
  1976年   42篇
  1974年   44篇
排序方式: 共有10000条查询结果,搜索用时 328 毫秒
1.
2.
3.
4.
5.
6.
7.
8.
9.
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC.  相似文献   
10.
We aim to assess the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, for men with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter, randomized, open-label, phase 2 trial. In our study, the enrolled mCRPC patients were randomized to 100, 200 and 300 mg dose groups at 1:1:1. The primary efficacy endpoint was prostate-specific antigen (PSA) response rate. The secondary endpoints included objective response rate (ORR), disease control rate (DCR) and time to PSA and radiographic progression. Safety and pharmacokinetics were also assessed. Finally, there were 108 patients from 17 centers being enrolled. By week 16, there were 13 (35.1%), 12 (36.4%) and 15 (42.9%) patients with confirmed 50% or greater PSA decline in 100 mg (n = 37), 200 mg (n = 33) and 300 mg (n = 35) groups, respectively. Among the 19 patients with target lesions at study entry, three (15.8%) had a partial response and 12 (63.2%) had stable disease. The ORRs of 20.0%, 22.2%, 0% and DCRs of 80.0%, 88.9%, 60.0% were, respectively, achieved in 100, 200 and 300 mg groups. By the maximum follow-up time of 24 weeks, there were 42.6% and 10.2% of cases experiencing PSA progression and radiographic progression, respectively. Overall, adverse events (AEs) were experienced by 94.4% of patients, most of which were mild or moderate. There were 28 patients experiencing ≥grade 3 AEs. The most common AEs were fatigue (17.6%), anemia (14.8%), elevated AST (14.8%) and ALT (13.0%), decreased appetite (13.0%). These findings preliminarily showed the promising antitumor activity of proxalutamide in patients with mCRPC with a manageable safety profile. The proxalutamide dose of 200 mg daily is recommended for future phase 3 trial (Clinical trial registration no. CTR20170177).  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号